11/12/09 – CAMBRIDGE, Mass.–( Business Wire)–Alnylam Pharmaceuticals, Inc. an RNAi therapeutics company, today announced that it will webcast its upcoming R&D Day live on the “Investors” section of the company’s website at www.alnylam.com. Alnylam’s R&D Day will be held on Thursday, November 12, 2009 from 8:30 a.m. to 12:00 p.m. ET
Alnylam scientists and management will review and provide updates on Alnylam platform advancements, delivery strategies, and pipeline of novel RNAi therapeutics. In addition, Alnylam will host two guest speakers:
- Professor Allan R. Glanville, Director of Thoracic Medicine and Medical Director Lung Transplantation, St. Vincent’s Hospital, Sydney, will discuss respiratory syncytial virus (RSV) infection in the lung transplant patient population; and,
- Professor Philip N. Hawkins, National Amyloidosis Centre, Division of Medicine, and University College London Medical School Royal Free Hospital, will discuss transthyretin (TTR)-mediated amyloidosis.
10/28/09 – CARLSBAD, Calif. & CAMBRIDGE, Mass.–(Business Wire)– Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. , and Isis Pharmaceuticals, Inc. , announced today that the United States Patent and Trademark Office (USPTO) has allowed a patent application within the `Esau` patent family (US Application Serial No. 10/909,125). The Esau patent estate, which is owned exclusively by Regulus, represents one of the earliest filings in the microRNA intellectual property landscape, and is fundamental to the discovery, development, and commercialization of microRNA therapeutics.
“Regulus is advancing a new class of innovative medicines based on microRNAs. Indeed, microRNA therapeutics represent a new frontier of pharmaceutical research where an entire pathway of human disease can be targeted,” said Kleanthis G. Xanthopoulos, Ph.D., President and Chief Executive Officer of Regulus Therapeutics. “This Notice of Allowance is the first in the Esau series, and we expect many more patents covering microRNA therapeutics to issue from this important and early patent family.”
Subscribe to the miRNA blog
Thank you for subscribing.
Something went wrong.